ProCE Banner Activity

CME

Diagnostic Approaches and Management Algorithm for Patients With AL Amyloidosis

Video

On-demand webcast of expert faculty presentation and case discussion on how to diagnose prior or light chain (AL) amyloidosis and apply a management algorithm for newly diagnosed patients.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: December 18, 2023

Expiration: December 17, 2024

Share

Faculty

Angela Dispenzieri

Angela Dispenzieri, MD

Consultant
Division of Hematology
Serene M. and Frances C. Durling Professor of Medicine and of Laboratory Medicine 
Mayo Clinic
Rochester, Minnesota 

Ashutosh Wechalekar

Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM

Professor of Medicine and Haematology
University College London
Honorary Consultant Haemetologist
University College Hospitals
Director, Jack O’Neil Laboratory
Department of Haematology
National Amyloidosis Centre
London, United Kingdom

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Alexion Pharmaceuticals; Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC; and Prothena Biosciences Limited.

Alexion Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Prothena Biosciences Limited

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with AL amyloidosis.

Program Learning Goal

The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare professionals to optimize diagnosis and management of patients with AL amyloidosis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current evidence and guideline recommendations for the diagnosis and management of AL amyloidosis via urgent biopsy and accurate precursor protein typing

  • Integrate into practice up-to-date efficacy and safety data on currently available and novel therapies to treat newly diagnosed and relapsed/refractory AL amyloidosis based on accurate risk and response assessment

  • Appraise ongoing clinical trials evaluating promising novel therapy for the treatment of patients with AL amyloidosis

  • Implement evidenced-based supportive measures for patients with AL amyloidosis that improve quality of life, relieve symptoms, and sustain organ function

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Angela Dispenzieri, MD

Consultant
Division of Hematology
Serene M. and Frances C. Durling Professor of Medicine and of Laboratory Medicine 
Mayo Clinic
Rochester, Minnesota 

Angela Dispenzieri, MD: researcher: Alexion, Alnylan, Bristol-Myers Squibb, Pfizer; consultant/advisor/speaker: Janssen, Sorento.

Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM

Professor of Medicine and Haematology
University College London
Honorary Consultant Haemetologist
University College Hospitals
Director, Jack O’Neil Laboratory
Department of Haematology
National Amyloidosis Centre
London, United Kingdom

Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM: consultant/advisor/speaker: Alexion, Attralus, Janssen, Prothena.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 18, 2023, through December 17, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.